Turkderm-Turk Arch Dermatol Venereol. 2022; 56(1): 61-66 | DOI: 10.4274/turkderm.galenos.2022.06337

Interleukin-23 Inhibitors

Esra Adýþen
Gazi University Faculty of Medicine, Department of Dermatology and Venereology, Ankara, Turkey

For adult patients with moderate to severe plaque psoriasis scheduled for systemic therapy, FDA-approved agents that act via interleukin-23 (IL-23) inhibition are guselkumab, tildrakizumab, and risankizumab. Response to treatment should be evaluated after a 12-week treatment period in psoriasis patients being treated with IL-23 inhibitors. In patients with partial response, dose increase may be planned, or topical corticosteroids, vitamin D analogs, methotrexate, or phototherapy (UVB) may be added to the treatment.

Keywords: IL-23 inhibitor, guselkumab, tildrakizumab, risankizumab

---

İnterkökin-23 inhibitörleri

Esra Adýþen
Gazi Üniversitesi Týp Fakültesi, Deri ve Zührevi Hastalýklar Anabilim Dalý, Ankara

Sistemik tedavi planlanan orta ve þiddetli plak tip psoriasisli eriþkin hastalarda interlökin-23 (IL-23) inhibisyonu yoluyla etki eden ajanlardan FDA onayý alanlar guselkumab, tildrakizumab ve risankizumabtýr. IL-23 inhibitörleri ile tedavi edilen psoriasisli olgularda tedaviye yanýt 12 haftalýk tedavi sonrasý deðerlendirilmelidir. Kýsmi yanýt veren hastalarda doz artýþý planlanabilir ya da tedaviye topikal kortikosteroidler, D vitamini analoglarý, metotreksat, fototerapi (UVB) eklenilebilir.

Anahtar Kelimeler: IL-23 inhibitörü, guselkumab, tildrakizumab, risankizumab

---

CITE